The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2024

Filed:

Feb. 25, 2022
Applicant:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Inventors:

Liang Deng, New York, NY (US);

Stewart Shuman, New York, NY (US);

Jedd Wolchok, New York, NY (US);

Taha Merghoub, New York, NY (US);

Weiyi Wang, New York, NY (US);

Peihong Dai, New York, NY (US);

Ning Yang, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 35/768 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/475 (2006.01); C07K 14/52 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0019 (2013.01); A61K 35/768 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55522 (2013.01); C07K 2317/76 (2013.01); C12N 2710/24032 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24143 (2013.01);
Abstract

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.


Find Patent Forward Citations

Loading…